Activation of Inflammasomes As A Triggering Mechanism of Glomerular Injury in Mice on the High Fat Diet

Krishna M. Boini,Min Xia,Chun Zhang,Justine M. Abais,Caixia Li,Pin-Lan Li

DOI: https://doi.org/10.1096/fasebj.25.1_supplement.1028.6

2011-01-01

Abstract:Inflammasome, an intracellular inflammatory machinery, is a multiprotein complex consisting of PYCARD, NALP, ASC and caspase 5 or caspase-1, which functions to switch on inflammatory process. The present study hypothesizedthat the formation and activation of inflammasomes are an important initiating mechanismresulting in obesity-associated glomerular injury. To test this hypothesis, C57BL/6J WT mice were fed control or high fat diet (HFD) for 0, 1, 3 and 5 weeks. HFD significantly increased the body weight, unfasted blood glucose levels and plasma visfatin concentration at week 3 and 5. RT-PCR showed that HFD increased the mRNA expression of NALP3, ASC and caspase-1 compared to control mice. Confocal fluorescent microscopy showed the presence of ASC, NALP3 and caspase-1 molecules in the glomeruli, but they were not colocalized in control mice. In the HFD mice, however, colocalization of NALP3, ASC and Caspase-1 was largely increased at week 3 and 5, accompanied by enhanced caspase-1 activity (by 1.3 fold), indicating the assembling and activation of NALP3inflammasomes or the inflammatory machinery. HFD treatment for 5 weeks further enhanced activation of inflammasomes and led to significant increases in the urinary total protein excretion, glomerular damage index, desmin expression and renal IL-1β production compared to control mice. In in vitro studies of podocytes, visfatin treatment increased the colocalization of NALP3 and ASC or Caspase 1 and it significantly enhanced the caspase activity, desmin expression, and IL-1β production. These effects of visfatin were substantially attenuated by prior treatment of ASC siRNA or WEHD, a caspase-1 inhibitor. We conclude thatthe formation and activation of inflammasomes in podocytes by adipokines such as visfatin may be importantly implicated in the development of obesity-associated glomerular injury (supported by NIH grants HL-091464, HL-75316 and DK54927).